Delaying type 1 diabetes
Teplizumab and other immunotherapy to delay type 1 diabetes.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 1, 1, 2, 4, 4.
New guidelines and consensus this year
All papers from the last 12 months
75 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- A Real-World Beta-Cell Preservation Framework in Type 1 Diabetes: Consensus from the T1D Exchange (T1DX-QI)Endocr Pract2026 Oct 16PMID 42887691Review
- US patterns in clinical islet autoantibody ordering and results show key differences after teplizumab regulatory approvalJ Clin Endocrinol Metab2026 Oct 16PMID 42138126
- Autoantibody Screening of Siblings in the Teplizumab Era: From a Single Measurement to Treatable Stages of Type 1 DiabetesDiabetes Obes Metab2026 Oct 6PMID 42834840
- Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 DiabetesDiabetes Care2026 Oct 1PMID 42520060
- [Immunotherapy and cell therapy in type 1 diabetes : Current state of research]Inn Med (Heidelb)2026 OctPMID 42517907Review
- Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responsesDiabetologia2026 OctPMID 42432282
- Assessing Extracellular Vesicle Proteins as Predictive Biomarkers for Developing Type 1 DiabetesProteomics2026 OctPMID 42163482
- Awareness drives willingness: Results of the ISPAD JENIOUS-PREME T1D project on parents' perspectives on disease-modifying therapy in T1DDiabet Med2026 Sep 29PMID 42808315
- [Expert insights on clinical application of immunotherapy for type 1 diabetes mellitus (2026 edition)]Zhonghua Yi Xue Za Zhi2026 Sep 29PMID 42778314
- SIRENA protocol: an Italian, prospective, multicentre cohort study of children and adults with islet autoimmunity and early-stage type 1 diabetesBMJ Open2026 Sep 21PMID 42767751
More endocrinology trends
All specialties →Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Once-weekly insulin
Basal insulins given once a week, such as insulin icodec.
Key point: No clinically relevant differences were observed in hypoglycemic event duration or characteristics between once-weekly efsitora and once-daily basal insulin groups.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
teplizumab[tiab] OR ("type 1 diabetes"[tiab] AND (prevention[tiab] OR delay[tiab]) AND immunotherap*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.